Ovarian tumours and adnexal masses encompass a broad spectrum of pathologies, ranging from benign cysts to aggressive malignancies. Accurate and early diagnosis is critical due to the high mortality ...

Current clinical methods used to identify epithelial ovarian cancer are often too late – when the cancer is at an advanced stage, leaving the patient with limited therapeutic options. Diagnosis is ...

Please provide your email address to receive an email when new articles are posted on . Four adnexal mass classification algorithms successfully distinguished lesions when used by a novice operator. A ...

BURLINGTON, N.C.--(BUSINESS WIRE)-- Laboratory Corporation of America ® Holdings (LabCorp ®) (NYSE: LH) announced today the nationwide availability of a new FDA cleared risk stratification tool (ROMA ...

AUSTIN, Texas, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease ...

Three-dimensional power Doppler (3DPD) ultrasound has been used for assessing adnexal masses, and in this study, we aimed to perform a meta-analysis to evaluate its role in the differential diagnosis ...

Aspira Women’s Health Inc. AWH has taken a significant step forward in advancing the clinical treatment of adnexal masses by entering into a definitive agreement with Dorsata, a healthcare software ...

In a landmark study, investigators from Europe propose a new and simple method to assess the risk of malignancy of women with an adnexal mass. The method identified between 89-99 percent of patients ...

LOS ANGELES More than a million women are living with ovarian masses. Twenty-two thousand of them will be told that they have cancer and more than 14,000 women will die this year. Traditional tests ...

About this issue Abstract OBJECTIVE To evaluate the performance of diagnostic prediction models for ovarian malignancy in all patients with an ovarian mass managed surgically or conservatively. DESIGN ...

AUSTIN, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, announced the commercial launch of ...